Premium
Combination immunotoxin treatment and chemotherapy in SCID mice with advanced, disseminated Daudi lymphoma
Author(s) -
Ghetie MariaAna,
Podar Erika M.,
Gordon Brian E.,
Pantazis Panayotis,
Uhr Jonathan W.,
Vitetta Ellen S.
Publication year - 1996
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/(sici)1097-0215(19960927)68:1<93::aid-ijc16>3.0.co;2-7
Subject(s) - immunotoxin , medicine , chemotherapy , lymphoma , oncology , cancer research , immunology , monoclonal antibody , antibody
We describe the use of an immunotoxin (IT) cocktail (anti‐CD22‐ and anti‐CD19‐ricin A chain) and any 1 of 3 chemotherapeutic drugs (doxorubicin, cytoxan or camptothecin) to treat advanced disseminated Daudi lymphoma in SCID mice (SCID/Daudi). In a previous report, we demonstrated that this regimen was curative when given the day following tumor cell inoculation. Here, we show that combination therapy in mice with advanced tumor significantly increased their survival, although it was not curative. Importantly, the outcome of therapy was dependent upon the temporal order in which IT and chemotherapy were administered. Thus, the best anti‐tumor effect was achieved when an IT cocktail was given before or at the same time as chemotherapy. When the IT was given after chemotherapy, there was no additional therapeutic benefit. Our results confirm the rationale of using combination therapy in the treatment of advanced B‐cell neoplasia and suggest that ITs should be administered prior to or during chemotherapy. © 1996 Wiley‐Liss, Inc.